Paradigm Therapeutics, Inc. announces investment from Eshelman Ventures, LLC

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S.C., May 6, 2025 /PRNewswire/ — Paradigm Therapeutics, Inc., a biopharmaceutical company, announces a $12.5 Million investment […]

Paradigm Therapeutics, Inc. announces the investment from Eshelman Ventures, LLC to support the completion of development of SD-101 (Zorblisa™), a topical therapy for the treatment of all skin surface areas of all subtypes of epidermolysis bullosa (EB).